These effects may influence Alzheimer's disease progression by modulating key pathological processes, including inhibition of beta-site amyloid precursor protein cleaving enzyme 1 and reduction of amyloid-β accumulation [27]. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.